Due to the prevalence of KEAP1 alterations in other malignancies, we sought to determine whether these mutations could represent an alternative driver of thyroid cancer, accounting for these unidentified mutations, or alternatively cooperate with other MAPK-activating mutations to further promote tumorigenesis. This evidence concerns the gene KEAP1 and thyroid gland carcinoma.